Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate fixed-dose intranasal esketamine plus an oral antidepressant in adults with treatment-resistant depression; results were posted a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• Oral antidepressant (unspecified)
• Spravato (esketamine) (esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Treatment-resistant Depression | Phase 3 | Status: COMPLETED | Results posted: 2019-04-18